STOCK TITAN

Perrigo Co Plc - PRGO STOCK NEWS

Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.

Overview

Perrigo Company Plc (PRGO) is a foremost global provider of over-the-counter consumer self-care products and affordable health solutions. With roots dating back to 1887, the company has evolved from packaging generic home remedies to a focused, pure-play consumer self-care business, specializing in a wide range of products from infant formulas to branded over-the-counter healthcare solutions.

Core Business and Product Portfolio

Perrigo operates across a spectrum of product categories that include store brand offerings and nationally recognized branded products. Its portfolio covers key segments such as infant formula for store brands, branded OTC products, and innovative health solutions like its pioneering over-the-counter daily birth control pill. With a robust blend of store brand and national brands, Perrigo’s business model is anchored on providing quality, accessible healthcare options that empower individuals to manage minor health conditions effectively.

Market Position and Global Presence

Positioned as one of the largest consumer health companies, Perrigo’s operations extend primarily across North America, Europe, Australia, and strategic markets in Asia and the Middle East. Its extensive distribution network includes major retailers such as Walmart, Amazon, Costco, and CVS, underscoring a resilient and expansive market reach. The company’s commitment to 'quality affordable healthcare products' is reflected in its tailored approach to meet diverse consumer needs, offering products that blend trusted efficacy with competitive pricing.

Business Model and Strategic Initiatives

Perrigo’s revenue is driven by a well-diversified product mix that leverages both private-label and branded offerings. Its transformation into a pure-play consumer self-care company was achieved through strategic divestments in areas such as animal health and generic pharmaceuticals, allowing a sharper focus on consumer self-care. The integrated business model maximizes profitability by reinvesting savings through operational efficiency programs and strengthening high-growth segments. Initiatives aimed at innovation and operational streamlining, such as the globally recognized Project Energize, underscore its commitment to maintaining competitive cost structures and enhancing product margins.

Innovation and Consumer-Focused Strategy

Innovation remains a cornerstone of Perrigo’s strategy. The company continuously invests in new product launches and refinements that align with evolving consumer needs and regulatory changes. Its recent advancements in the reproductive health space—exemplified by partnerships that enhance health education and access—demonstrate a commitment to addressing critical areas of consumer well-being. Such initiatives not only reinforce brand strength but also contribute to market differentiation within the competitive landscape of OTC health and wellness solutions.

Industry Expertise and Differentiation

Perrigo’s long-established presence and expertise in the consumer health arena are backed by decades of operational excellence and strategic leadership. The company’s ability to consistently deliver high-quality, affordable products positions it uniquely among its peers. Detailed management succession plans and operational transitions further exemplify its robust internal expertise and focus on sustaining long-term value creation. By harnessing a blended-branded approach, Perrigo successfully addresses various consumer demographics, ensuring accessibility to essential health products across multiple price points.

Conclusion

Overall, Perrigo Company Plc remains an influential force in the global consumer self-care market. Its commitment to quality, affordability, and continuous innovation serves as a testament to its proven business model. For investors and market analysts alike, Perrigo offers a comprehensive case study in achieving market resilience and operational excellence in a rapidly evolving healthcare landscape.

Rhea-AI Summary
Perrigo Company plc (PRGO) announces the availability of Opill®, the first daily birth control pill without a prescription in the U.S., for pre-order and in-store purchase at major retailers nationwide. Opill® is FDA-approved and priced at $19.99 for one-month and $49.99 for three-month packs. It aims to address barriers to contraceptive access and is 98% effective. Opill® is a significant advancement in reproductive health, offering a convenient and affordable option for preventing unintended pregnancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) to present at UBS Global Consumer and Retail Conference. President and CEO, Patrick Lockwood-Taylor, and CFO, Eduardo Bezerra, to speak on March 13th. Webcast available on Perrigo's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
-
Rhea-AI Summary
Perrigo Company plc (PRGO) achieved record net sales in the fourth quarter and fiscal year 2023, with improvements in gross profit, operating income, and EPS. The company launched 'Project Energize' to drive sustainable growth. Despite challenges in organic net sales, the company reported positive results and outlined future outlooks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.14%
Tags
News
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) increases its quarterly dividend by 1% to $0.276 per share, marking the 21st consecutive year of dividend growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.14%
Tags
dividends
-
Rhea-AI Summary
Perrigo Company plc (PRGO) is set to release its fourth quarter and fiscal year 2023 financial results on February 27th, 2024. The earnings conference call will be accessible via webcast or phone, with a replay available until March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) announced the early tender results of its cash tender offer to purchase its 3.900% Senior Notes due 2024 in a principal amount of up to $300,000,000. The total principal amount of Notes validly tendered and not withdrawn as of the Early Tender Date is $385,548,000, representing 42.86% of the outstanding principal amount. The Tender Offer will expire on December 12, 2023, with settlement expected on December 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) Announces Commencement of Cash Tender Offer for Its 3.900% Senior Notes due 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Summary
Perrigo Company plc (PRGO) reported a third-quarter net sales increase of 2.2% to $1.1 billion, with organic net sales decreasing 1.2%. The company achieved a gross margin of 36.6% and an adjusted gross margin of 39.5%. Reported EPS was $0.11, compared to a loss of $(0.39) in the prior year quarter. The company updates its fiscal 2023 organic net sales and total net sales growth outlook range to 1.0%-3.0% and 4.0%-6.0%, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
-
News
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.273 per share. The dividend will be payable on December 19, 2023, to shareholders of record on December 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
dividends
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Patrick Lockwood-Taylor, and CFO Eduardo Bezerra will participate in investor meetings at the Jefferies Consumer Conference on November 15th, 2023, and present at the Morgan Stanley Consumer & Retail Conference on December 6th, 2023. Interested parties can access the webcast on the Perrigo website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences

FAQ

What is the current stock price of Perrigo Co Plc (PRGO)?

The current stock price of Perrigo Co Plc (PRGO) is $27.7 as of April 1, 2025.

What is the market cap of Perrigo Co Plc (PRGO)?

The market cap of Perrigo Co Plc (PRGO) is approximately 3.8B.

What products does Perrigo offer?

Perrigo offers a diverse range of over-the-counter self-care products including infant formulas, branded healthcare items, and store-brand OTC products designed to address everyday health needs.

How has Perrigo evolved over the years?

Founded in 1887 as a provider of generic home remedies, Perrigo has transformed into a specialized consumer self-care company focusing on high-quality, affordable OTC health solutions.

What is Perrigo's core business model?

Perrigo’s business model centers on a blend of private-label and national brand products, leveraging operational efficiencies and strategic divestments to concentrate on consumer self-care and OTC health solutions.

Which markets are key to Perrigo's global presence?

Perrigo primarily operates in North America, Europe, and Australia, with additional strategic markets in Asia and other regions, supported by a robust distribution network with major retailers.

How does Perrigo differentiate itself from competitors?

The company differentiates itself through its long-standing focus on affordability, high-quality products, and continuous innovation, coupled with operational efficiency programs and a diversified product mix.

What recent innovations has Perrigo introduced?

Recent innovations include breakthrough products such as the first over-the-counter daily birth control pill, which reflect Perrigo’s commitment to consumer health education and accessibility.

How does Perrigo maintain its commitment to affordable healthcare?

Perrigo reinforces affordability by streamlining its operations, focusing on high-volume store-brand products, and reinvesting cost-saving initiatives into developing and enhancing consumer self-care solutions.

What strategic initiatives support Perrigo's business transformation?

Key initiatives such as Project Energize are instrumental in driving operational efficiencies and margin expansion, supporting the company’s strategic transformation into a pure-play consumer self-care leader.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Stock Data

3.77B
135.94M
0.34%
101.68%
3.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2